TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> or = 18 years of age~* Clinical diagnosis-abnormal heart beat known as atrial fibrillation/flutter (ECG documentation)~* Able to swallow pill form of drug~Exclusion Criteria:~* \< 18 years of age~* enrollment in another ongoing trial~* paroxysmal atrial fibrillation~* hemodynamic instability~* atrial fibrillation ablation within 6 months of enrollment~* a contraindication for anticoagulation~* severe valvular heart disease~* presence of single lead implantable cardioverter defibrillator~* unstable angina~* New York Heart Association (NYHA) Class IV heart failure~* hyperthyroidism~* uncontrolled hypertension (blood pressure \> 180/100 at rest) on medications~* an illness that would limit life expectancy to less than 1 year~* use of statins within the previous 30 days~* significant coronary artery disease or lipid abnormalities necessitating statin therapy~* implanted devices for active management of arrhythmias by pacing or defibrillation~* lack of access to a telephone~* illicit drug use~* alcohol abuse~* hypersensitivity to atorvastatin by history~* pregnancy~* sexually active female subjects not on contraception or surgically sterilized~* nursing mothers~* chronic liver disease or abnormal liver function (elevated transaminases 1.5 times the upper limit of normal \[ULN\] of laboratory reference range)~* severe renal disease (creatinine \> 200 mmol/L)~* inflammatory muscle disease or creatine kinase (CK) \> 3 times ULN~* concurrent treatment with cyclosporine, fibrates, or high-dose niacin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo taken daily
- Atorvastatin (Type: EXPERIMENTAL): Atorvastatin at a dose of 80 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Revaccination of Young Children With Bacille Calmette Guerin (BCG) Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No overt illness~Exclusion Criteria:~* PPD reaction \>15mm

- Gender: ALL
- Minimum Age: 19 Months
- Maximum Age: 24 Months
- Healthy Volunteers: None

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Laparoscopic Hysterectomy Via a Single Port, Peri-umbilical Technique Versus a Conventional Laparoscopic Technique

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient is available for 12 months of follow-up~* The patient is declared fit by the anesthetist for an intervention by laparoscopy~Exclusion Criteria:~* The patient is not available for 12 months of follow-up~* The patient is participating in another study or is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient is not insured or beneficiary of a health insurance plan~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient cannot read French~* Patient with a history of pelvic radiotherapy~* Patient with a history of pelvic surgery or serious risk of major adhesions~* The patient is pregnant~* Contraindications for anesthesia for either surgical technique~* Promontofixation or lymphadenectomy~* No associated procedure other than morcellation or vaginal suture for extracting the hysterectomy specimen, unilateral or bilateral oophorectomy~* The patient has a known or suspected allergy to polyurethane~* Extended hysterectomy for neoplastic disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peri-umbilical single-port (Type: EXPERIMENTAL): Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.~Intervention: Single-port, peri-umbilical hysterectomy
- Multi-port (Type: ACTIVE_COMPARATOR): Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.~Intervention: Multi-port hysterectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intense Aerobic Exercise on the Cerebrovascular Reserve Capacity in Patients With Hemodynamically Relevant Intra- and Extracranial Stenoses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* high-grade stenosis of the intra- or extracranial ICA or the MCA with ipsilateral impairment of the CVR capacity measured by TCD~Exclusion Criteria:~* continuous physical activity ≥ 60 min/week within the last 3 months~* cerebral bleeding or ischaemic stroke \< 3 months~* contraindications for spiro-ergometry, IAEx, or MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sedentary (Type: NO_INTERVENTION): patients who train after an 8 week observational period
- patients who train immediately after enrollment (Type: ACTIVE_COMPARATOR): patients who train immediately after enrollment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* understand and sign informed consent~* willing to undergo night blood sampling every 6 months for 2 years~* Age 18 to 55 years~* Haemoglobin of equal or above 9g/dl~* Microfilarial level of equal or above 80mg/dl~Exclusion Criteria:~* Non- consenting~* Pregnancy or lactation~* Treatment with albendazole or ivermectin within the previous 6 months~* Known allergy to the study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- albendazole 400mg and ivermectin 200mcg/kg (Type: ACTIVE_COMPARATOR): Annual treatment
- Albendazole 800mg and ivermectin 400mcg/kg (Type: ACTIVE_COMPARATOR): Annual treatment
- Albendazole 400mg and ivermectin 200mcg/kg (Type: ACTIVE_COMPARATOR): albendazole 400mg and ivermectin 200mcg/kg given twice a year
- Albendazole 800mg and ivermectin 400mcg /kg bi-annually (Type: ACTIVE_COMPARATOR): Albendazole 800mg and ivermectin 400mcg/kg given twice a year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathological confirmed melanoma 2. Advanced stage confirmed by radiological examination 3. Untreated 4. ECOG PS 0-1 6. Good organ function 7. No other severe diseases such as autoimmune disease, organ transplant, chronic infection.~8. Other tumor disease.~Exclusion Criteria:~1. Symptomatic brain metastases~2. Active infection~3. Active HBV or HCV infection~4. HIV infection~5. Autoimmune disease~6. Sensitive to drug or ingredients~7. Severe mental disorders~8. Sever disfunction of heart, liver and kidney

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- L-TIL and Tislelizumab (Type: EXPERIMENTAL): L-TIL（3-10）x10\*9/m2, Q3W, 4 cycles Tislelizumab 200mg, iv, Q3W, 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Organ Protection by Remote Ischemic Preconditioning for Surgical Treatment of Pediatric Congenital Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* congenital heart surgery~Exclusion Criteria:~* hypoplastic left heart syndrome

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Remote ischemic preconditioning (Type: EXPERIMENTAL): Remote ischemic preconditioning at the left leg.
- Control (Type: NO_INTERVENTION): No ischemic preconditioning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immunotherapy in Treating Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic breast cancer that expresses carcinoembryonic antigen (CEA)~  * At least 25% of the tumor cells must stain positive for CEA with at least moderate intensity~* Must have achieved either partial response or complete response after high dose chemotherapy and peripheral blood stem cell transplant~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Menopausal status:~* Not specified~Performance status:~* Karnofsky 70-100%~Life expectancy:~* Greater than 6 months~Hematopoietic:~* Absolute neutrophil count at least 1000/mm\^3~* Absolute lymphocyte count at least 1000/mm\^3~* Hemoglobin at least 9 mg/dL~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin less than 2.0 mg/dL~* No serious ongoing chronic or acute hepatic disease~Renal:~* Creatinine less than 2.5 mg/dL~Cardiovascular:~* No serious ongoing chronic or acute cardiac disease (New York Heart Association class III or IV)~Pulmonary:~* No serious ongoing chronic or acute pulmonary illness such as asthma, chronic obstructive pulmonary disease, or radiation or drug induced pneumonitis~Other:~* No other prior or concurrent malignancy except nonmelanoma skin cancer or controlled superficial bladder cancer within the past 5 years~* No history of autoimmune disease such as inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, scleroderma, or multiple sclerosis~* No inflammatory bowel condition such as active infectious enteritis or eosinophilic enteritis~* No active acute or chronic infection such as urinary tract infection, HIV, or viral hepatitis~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~* No concurrent immunotherapy~Chemotherapy:~* See Disease Characteristics~* No concurrent chemotherapy~Endocrine therapy:~* At least 4 weeks since steroids~* No concurrent steroid therapy~Radiotherapy:~* No concurrent radiotherapy~Surgery:~* Not specified~Other:~* No concurrent immunosuppressive agents such as azathioprine or cyclosporine A

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- carcinoembryonic antigen RNA-pulsed DC cancer vaccine (Type: EXPERIMENTAL): carcinoembryonic antigen RNA-pulsed DC cancer vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pediatric or adult patients with chronic neuromuscular disorders, such as spinal muscular atrophy, Duchenne muscular dystrophy, other congenital myopathy, or amyotrophic lateral sclerosis (ALS), hospitalized for acute respiratory failure, as defined by:~* Persistent bronchial encumbrance (\> 2 days) despite regular treatment in the homecare setting, associated with-Oxygen desaturation on room air, defined by a pulse oximetry (SaO2) \<95%) or~* In patients not receiving long-term NPPV: the need to institute NPPV-In patients receiving long-term NPPV: the need to increase the daily length of NPPV by at least 25%.~Exclusion Criteria:~* Need for immediate intubation (alteration in consciousness, coma, hemodynamic disorders)~* Multiple organ failure (e.g., associated cardiac failure)~* In adults: respiratory rate \>30/min, pH \< 7.35, PaCO2 \> 50 mm Hg~* Facial deformity or anomaly which prevents the use of a mouthpiece or mask~* Patients who signed a refusal to be intubated regardless of the progression of their disease~* Patients on long-term oxygen therapy~* Tracheotomized patients~* Patients requiring the use of an intrapulmonary percussive ventilation device during hospitalization~* Acute neuromuscular disorder of known or unknown etiology~* Associated lung disease such as chronic obstructive pulmonary disease (COPD)~* Refusal of patient consent and/or parental consent in the case of a minor~* Uncooperative patients~* Patients \< 4 years old

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): patients treated with standard treatment and a mechanical insufflation-exsufflation
- 2 (Type: ACTIVE_COMPARATOR): Patients with standard treatment and standard respiratory physiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-proven DLBCL which meet the criteria of any of the 4 subgroups~* Transformed DLBCL from a previous indolent NHL which meet the criteria of any of the 4 subgroups and have received at least one standard chemotherapy regimen for aggressive NHL or a biopsy upon progression of disease has been obtained to confirm the presence of DLBCL. The concomitant presence of a component of low grade lymphoma will NOT exclude participation~* Measurable disease per Standardized Response Criteria for Non-Hodgkin's Lymphoma~* Prior gemcitabine therapy is allowed.~* Negative pregnancy test~Exclusion Criteria:~* No history of life-threatening reactions to rituximab.~* No history of gemcitabine intolerance; prior gemcitabine therapy is allowed.~* No history of malignancy in the last 5 years (basal cell carcinoma of the skin excluded).~* No central nervous system or cerebrospinal fluid involvement~* No other investigational drugs received within 30 days prior to being registered for protocol therapy.~* No active infections.~* No current breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Rituximab + Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Retrieval Study and Histological Examination Of A Hip Femoral Components With Hydroxyapatite Coatings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Fractured neck of femur requiring hemi-arthroplasty. Selection of subjects for this evaluation should include the following considerations:-.~* A likelihood of obtaining relief of pain and improved function.~* Full skeletal maturity.~* Ability to follow instructions.~* Good general health for age.~* Willing to return for follow-up evaluations .~* No bias to sex.~Exclusion criteria:~• None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Stem with plasma sprayed porous Titanium 6Al4V alloy + Plasma sprayed HA
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Abraxane Injection Into Pancreatic Cysts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Mucinous cysts (premalignant or malignant cysts of the pancreas)~* Normal organ and marrow function~* Baseline CT within 6 months of enrollment~Exclusion Criteria:~* Pregnant or breastfeeding~* Acute active pancreatitis~* Complicated pancreatic cysts~* Subjects who do not speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albumin bound paclitaxel (Type: EXPERIMENTAL): Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients primarily referred for disabling, unexpected fatigue.~* According to the Fukuda criteria, diagnostic work-up yields a final diagnosis of chronic fatigue (CF) or chronic fatigue syndrome (CFS).~* 18 \<= age \<= 65~* Polysomnography Test (PSG) demonstrates an apnea-hypopnea index (AHI) \>=15, as evidence for obstructive sleep apnea (OSA).~* Female patient of childbearing potential (premenopausal female biologically capable of becoming pregnant) has a confirmed negative pregnancy test at the start of the Continuous Positive Airway Pressure (CPAP) trial and has to employ an acceptable method of birth control.~* Written, signed and dated informed consent must be obtained from each patient.~* Patient able to understand and follow the requirements of the study and to comply.~* Willing to abstain from taking any medication or treatment prohibited in the protocol.~Exclusion Criteria:~* Patients primarily referred for Excessive Daytime Sleepiness (EDS) or snoring.~* Fatigue that is explained by medical or psychiatric causes.~* 18 \> age \> 65~* Apnea-Hypopnea Index (AHI) \< 15~* Body Mass Index (BMI) \>= 40, calculated as weight(m)/(height (m))²~* Parasomnia~* Severe sleepiness with (Epworth Sleepiness Scale) ESS \>= 16 (=15% of the Chronic fatigue syndrome (CFS) population)~* Tonsillar hypertrophy (Friedman grade III and IV tonsils)~* Signs of nasal obstruction, including chronic use of topical nasal drugs.~* Earlier CPAP treatment~* Physical and mental disability that compromises the normal use of CPAP~* CPAP intolerance~* Current use of sedative (benzodiazepine and non-benzodiazepine GABA-esgic agonist) or antidepressant medication for a time period inferior to 3 weeks.~* Female patient who is pregnant, lactating or has a positive pregnancy test result.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active/Sham CPAP (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues